Johnson & Johnson Reaches All-Time High Following UBS Buy Recommendation
Shares of Johnson & Johnson (JNJ) hit an all-time high on Wednesday, driven by a new 'Buy' recommendation from UBS with a $320 price target. The investment bank expects the company to shift toward being viewed as a growth stock due to its strong product pipeline. UBS's coverage initiation highlights confidence in Johnson & Johnson’s future performance and innovation potential within the pharmaceutical sector, contributing to increased investor interest.
